Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

FDA approval of Jemperli delivers a new royalty stream for AnaptysBio, backed by strong data.

What the company is saying

AnaptysBio announces that GSK has received FDA approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The company highlights multiple regulatory achievements: FDA Fast Track, Breakthrough Therapy, Priority Review, and a National Priority Voucher, all culminating in accelerated approval ahead of the February 2027 PDUFA date. The announcement emphasizes robust clinical efficacy from the AZUR-1 trial, with 68% of patients achieving sustained clinical complete response at 12 months and no disease recurrences among responders after two years. Safety data are presented transparently, including 20% serious adverse reactions and a 3% discontinuation rate. The tone is factual and confident, focusing on the clinical and regulatory milestones rather than speculative commercial projections. AnaptysBio frames its role as manager of financial collaborations for Jemperli with GSK, aiming to protect and return royalty value to shareholders.

What the data suggests

The AZUR-1 trial showed that 68% (98/144; 95% CI: 60%, 76%) of evaluable patients achieved a sustained clinical complete response at 12 months, with an exploratory analysis indicating 76% (110/144; 95% CI: 69%, 83%) had no evidence of cancer one year or more after treatment. Among those, 68% reached cCR12 without surgery, and 12 additional patients achieved pathological complete response after surgery. No disease recurrences have been reported among responders after a median follow-up of more than two years. Independent central review data are still maturing, with 47% (54/116; 95% CI: 37%, 56%) achieving cCR12. Safety data show serious adverse reactions in 20% of patients, with fatigue (32%), rash (22%), diarrhea (18%), and pruritus (17%) as the most common side effects; 3% discontinued treatment due to adverse reactions. The approval was granted ahead of the scheduled PDUFA date, reflecting regulatory confidence in the data. The announcement does not disclose any royalty, revenue, or financial impact figures, so the direct financial benefit to AnaptysBio remains unquantified, but the approval is a clear operational milestone.

Analysis

The announcement is proportionate in tone, focusing on the FDA approval of Jemperli for a new indication, which is a realised and material milestone. The claims are substantiated by detailed clinical trial data, including efficacy and safety outcomes, and the regulatory achievements are clearly documented. Only a small fraction of the content is forward-looking (e.g., upcoming data presentations and ongoing international regulatory reviews), and these are routine next steps rather than aspirational projections. There is no evidence of exaggerated language or narrative inflation; the release avoids overclaiming future commercial impact or financial upside. However, the absence of any financial metrics (royalty income, revenue, or profit) means the investment signal cannot be rated above weak_positive, as per the Disclosure Completeness Rule. The benefits of the FDA approval are immediate, with no large capital outlay or long-dated, uncertain returns discussed.

Risk flags

• ●The absence of disclosed royalty or revenue figures means investors cannot assess the immediate financial impact of this approval for AnaptysBio, limiting visibility into the scale of value creation.
• ●While the clinical data are strong, 20% of patients experienced serious adverse reactions and 3% discontinued treatment, which could affect long-term adoption and market penetration.
• ●Regulatory reviews are still ongoing in countries outside the U.S., so international market access and additional revenue streams are not yet secured.
• ●The durability of clinical benefit is promising but based on a median follow-up of just over two years; longer-term outcomes and real-world effectiveness remain to be validated.
• ●Jemperli is approved for a biomarker found in only 5-10% of rectal cancers, which limits the addressable patient population and thus the potential royalty upside.

Bottom line

AnaptysBio stands to benefit from a new royalty stream following FDA approval of Jemperli for MSI-H/dMMR locally advanced rectal cancer, supported by strong efficacy (68% cCR12 at 12 months) and no reported disease recurrences after two years. The safety profile is consistent with prior data, though 20% serious adverse reactions and a 3% discontinuation rate could temper uptake. The company does not disclose any financial metrics tied to this approval, so the magnitude of near-term royalty income is unclear. International regulatory reviews are ongoing, and further clinical data will be presented imminently at ESMO Congress. The most important takeaway is that AnaptysBio has achieved a major operational milestone with immediate U.S. market relevance, but investors will need future disclosures to quantify the financial impact.

Announcement summary

(NASDAQ:ANAB) AnaptysBio, Inc. announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer. Jemperli received FDA Fast Track and Breakthrough Therapy designations for this indication. The application was granted Priority Review and received the National Priority Voucher, resulting in accelerated approval ahead of the February 2027 PDUFA date. This approval is supported by data from the AZUR-1 trial, which met its primary objective by showing a significant proportion of participants achieved sustained clinical complete responses at 12 months (cCR12), with data continuing to mature. Investigator-assessed data showed 68% of evaluable patients (98/144; 95% CI: 60%, 76%) achieved cCR12. In an exploratory analysis, 76% (110/144; 95% CI: 69%, 83%) of evaluable patients had no evidence of cancer one year or more after treatment. This includes 68% (98/144) (95% CI: 60%, 76%) of patients who reached cCR12 without surgery, plus 12 participants who had their complete response confirmed through tissue analysis after surgery (pathological complete response, or pCR). No disease recurrences have been reported among responders to date, after a median follow up of more than two years. Data on the primary objective, cCR12 assessed by independent central review, continue to mature, with 47% (54/116) (95% CI: 37%, 56%) of evaluable patients achieving cCR12. An additional 38 participants who are still progressing through to 12 month follow up have already achieved a clinical complete response. The safety profile of Jemperli was generally consistent with its established profile across solid tumors. Serious adverse reactions occurred in 20% of patients receiving Jemperli. The most common adverse reactions were fatigue (32%), rash (22%), diarrhea (18%), and pruritus (17%). Jemperli was permanently discontinued due to adverse reactions in 3% of patients. GSK plans to present full data from the AZUR-1 interim analysis as a late-breaking abstract at ESMO Congress 2026 in Madrid, Spain on October 25, 2026. The current standard of treatment for locally advanced rectal cancer includes chemotherapy, radiation, and surgery, which can have lasting consequences. For patients with MSI-H/dMMR tumors, a biomarker found in around 5-10% of rectal cancers, Jemperli monotherapy could help avoid these interventions. The AZUR-1 sBLA is being reviewed under Project Orbis, an FDA Oncology Center of Excellence initiative that enables concurrent review by international health authorities, and regulatory reviews are ongoing in participating countries. Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. In the United States, Jemperli is currently approved for endometrial cancer, rectal cancer, and dMMR solid tumors, and is being studied as monotherapy in colon cancer and head and neck squamous cell carcinoma. Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a Collaboration and Exclusive License Agreement signed in March 2014. Under this agreement, GSK is conducting ongoing research, development, commercialization, and manufacturing of Jemperli. AnaptysBio manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, focusing on protecting and returning the value of its royalties to shareholders.

Disagree with this article?